Linical
Accelovance is an award-winning, clinical development CRO focused on oncology & immunology programs across phase I-IV. Accelovance has conducted 150+ oncology trials across the globe, spanning many tumor types. The team’s immuno-oncology experience includes immune checkpoint modulators, cellular immunotherapies, oncolytic viruses, peptide vaccines & more. The HERO Initiative by Accelovance is a specialized early phase oncology program providing emerging and established biotech and pharmaceutical companies an accelerated means of advancing early phase cancer compounds through clinical testing.